السلامُ عليك أيها النبي، نذكرُك ونحبك زيادةً كلما رأينا ثمار غرسك في أمتك؛ مجاهدين وصابرين ومقاومين ومؤمنين وشهداء أعزاء بالدين لا تكسرهم الشدة ولا يُرهبهم تكالب أعدائهم عليهم. شكرًا مرسال لدعم فلسطين! 

सर्वे भवन्तु सुखिनः, सर्वे सन्तु निरामयाः ।
सर्वे भद्राणि पश्यन्तु, मा कश्चिद् दुःखभाग् भवेत् ॥

I believe fungi research is our best hope for a healthy future Earth. In memory of Muriel Martin.

High quality medical services for marginalized groups in Cairo and the region.

Mersal Foundation for Charity and Development is a non-profit organization that serves in the health field and works on providing all types of healthcare with high quality to whoever is in need.

**Vision**
To be the number one medical organization in Egypt and the Arab region and proactive in ensuring the right in healthcare for the marginalized groups and those who are in need the most.

**Message**
Working on analyzing and filling the gaps of the healthcare system to provide high quality medical services on the basis of equality and dignity through enabling a charitable healthcare system for whoever cannot afford it, as well as contributing to the development of the health sector.

**Objectives**  

- Providing medical services to whoever deserves them regardless the cost or for how long they will be needed.
- Spreading medical awareness in all the places it serves in.
- Achieving sustainability in funding its activities Core Values.
- Privacy: Mersal ensures the patient's eligibility to receive its services without hurting their dignity or exposing them to any kind of embarrassment.
- Healthcare With No Discrimination: Mersal is an open arm to all patients with no discrimination whatsover; whatever religion, nationality, color, or language, all patients in need are welcomed to receive the organization services.
- High Quality: Mersal provides all types of medical services in the highest possible quality through its network of specialized medical personnel.
- Credibility and Transparency: Mersal announces the size and sources of its fund as well as its administrative and medical expenditures, The foundation financial reports and annual budgets are available through several outlets through which any person can explore how resources are managed. Mersal believes in the importance of being specialized in specific fields and its early choice was the healthcare services.

In the past six years, the organization registered over 25,000 patients from 27 provinces.  Mersal has been seeking to enable access to its services all over the country. And the dream of helping those who are in need whoever they are and whatever the cost and time is still alive, Mersal has worked over the past six years on getting close to its patients throughout their treatment journey.

Mersal Foundation for Charity and Development 

The Fungi Foundation is a global organization that works for the Fungi, their habitats, and the people who depend on them.

Launched in 2012, the Fungi Foundation is the first NGO dedicated to the fungi kingdom. Since its inception, it has achieved numerous milestones while dedicating itself to exploring the fungi world in view of increasing knowledge of their diversity, educating about their applications, and recommending public policy for their conservation. As part of our ongoing 3F initiative, the foundation played a key role in enabling Chile to become the first country in the world to include protection of fungi in its environmental legislation. More recently, the foundation proudly announced the Fantastic Fungi Education Curriculum, the world's first mycological set of courses designed for schools.

In short, the Fungi Foundation envisions a healthy planet in which Fungi are recognized, protected, and embraced as the interconnectors of nature; a mission that would be impossible without the essential support of our kind, engaged donors.

Fungi Foundation

Cuddles Foundation nourishes children in their fight against cancer. Because #Foodheals



**Feed Children. Starve Cancer.**

Every year, approximately 76,000 children in India may develop cancer, with 58% of them being severely malnourished at the time of diagnosis. For these children, nutrition can mean the difference between life and death. Every child deserves a chance at a cure, and we are here to make that happen.

At Cuddles Foundation, we partner with over 40 government and charity cancer hospitals to support children through our FoodHeals program. Our mission is to ensure that children undergoing cancer therapy receive comprehensive nutritional support. This includes access to trained clinical pediatric nutritionists, expert dietary counsel, supplements, hot meals, monthly ration baskets, and caregiver support. Good food helps the medicine work!

This multi-pronged approach tackles a simple but often ignored aspect of a child’s successful recovery from cancer. While undergoing treatment, it is essential that children have freshly prepared, nutritious food in sufficient quantity and don't stay hungry for long periods. The impact of our work is evident. When part of the FoodHeals Program, 82%* of patients improved or maintained their nutritional status, despite cancer therapy like chemotherapy or radiation.

Additionally, 96% of children followed up* on their treatment plan when nutrition was a part of it, demonstrating the program’s effectiveness. Besides the love and affection of our patients, their families, and our supporters, we’ve won some prestigious awards along the way. This includes the National Award for Child Welfare (2015-16), the Akshaya Patra and UN Global Compact Award (2018) and most recently we received the Global CSR & ESG Awards 2024 - Top 10 Best NGOs of the Year (2024).

Join us in our mission to nourish hope and fight childhood cancer. Your support can make a world of difference.

**As per Cuddles annual impact statistics 2023-24*
**Follow-up treatment rate: Patients who returned for a second visit or continued treatment when nutrition was a part of it.*

Cuddles Foundation

Extending and improving the lives of people with ALK+ lung cancer by raising funds for research and patient support programs.

**Our Vision**

We envision a world where ALK+ lung cancer is a chronic or even curable condition and the next person diagnosed with lung cancer does not have to live under the current stigma.

**Our Start**

\#SweatForBreath started as a grassroots fundraising campaign during Lung Cancer Awareness Month in 2023. After being diagnosed with Stage IV ALK+ lung cancer in November 2022, David Cornbrooks became keenly aware that he was benefiting from the selfless fundraising and awareness efforts of the patients before him.

[Listen to David's story here.](https://www.youtube.com/watch?v=lWcS-yN7Qxw)

The \#SweatForBreath campaign in 2023 became David, and his wife, Lisa’s, way to help the next generation ALK+ lung cancer patients.

\#SweatForBreath accelerated beyond more than just a typical fundraiser.  The initiative quickly evolved into a community of patients, caregivers, family, and friends seeking to make David and Lisa's vision a reality and the road to that vision more tolerable. People donated, sweat at the in-person cycle event, posted on social media, and helped fundraise through organizing group walks, selling art, "gifting" donations on behalf of clients, and much more.

Their success in 2023 compelled David and Lisa to officially transition the \#SweatForBreath campaign into the Sweat For Breath Foundation, operating through a fiscal sponsorship with Players Philanthropy Fund, a Maryland charitable trust recognized by IRS as a tax-exempt public charity under Section 501(c)(3) of the Internal Revenue Code (Federal Tax ID: 27-6601178).

**Our Impact**

Since 2023, over **1,450 donors** have given nearly **$400,000** to the Foundation (or its predecessor campaign). 100% of the proceeds have gone directly to The Johns Hopkins Sidney Kimmel Center in Baltimore, MD to support Dr. Vincent Lam’s ALK+ lung cancer research.

This support provided the critical funding needed to launch Dr. Lam’s clinic trial, which will evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy. Dr. Lam’s vaccine is the **first ALK+ vaccine in the world** to be tested in a clinical trial. Dr. Lam administered the vaccine to the first patient **in clinic on May 13, 2024**!

-----------

*The Sweat for Breath Foundation is a project of Players Philanthropy Fund, Inc. a Texas nonprofit corporation recognized by IRS as a tax-exempt public charity under Section 501(c)(3) of the Internal Revenue Code (Federal Tax ID: 27-6601178,[ppf.org/pp](https://ppf.org/pp)). Contributions to The Sweat for Breath Foundation qualify as tax-deductible to the fullest extent of the law.*


The Sweat For Breath Foundation

Zig is a general-purpose programming language and toolchain for maintaining robust, optimal, and reusable software.

The Zig Software Foundation is a non-profit corporation founded in 2020 by Andrew Kelley, the creator of Zig, with the goal of supporting the development of the language. Currently, the ZSF is able to offer paid work at competitive rates to a small number of core contributors. We hope to be able to extend this offer to more core contributors in the future.

Zig Software Foundation Inc

We match donations to any charity you choose while introducing you to super-effective charities. Learn more: GivingMultiplier.org

[**Giving Multiplier**](https://givingmultiplier.org) is a research project created at Harvard University that adds matching funds to any charity of your choice while introducing donors to highly effective charities recommended by experts.

*Resources:*

- [Make a donation that gets matched](https://givingmultiplier.org)
- [Become a matching funder](http://givingmultiplier.org/matching) (Donations made on this page will also go toward our matching system.)
- [Sign up to our newsletter](http://eepurl.com/i0GHhc)
- [Learn about our philosophy](https://givingmultiplier.org/philosophy)

Questions? Email us: **info@givingmultiplier.org**

Giving Multiplier

Supporting research on the welfare of neglected animals.

There are millions of known arthropod species. There are doubtless millions more. And there may be quintillions of individual arthropods.

We know little about most of these animals and, as a result, little about how their welfare might be improved in contexts where humans use, manage, or otherwise affect them.

The mission of the Arthropoda Foundation is to support research on the welfare of arthropods. We value both basic and applied projects. We are particularly interested in research with a clear path to impact, whether by shaping future science or informing real-world decision-making.

Arthropoda Foundation

We are a research hospital that treats patients in all medical disciplines, focusing on oncology, neurology, and diagnosis.

The Fondazione Casa Sollievo della Sofferenza – Opera di San Pio da Pietrelcina (transl. Home for the Relief of Suffering Foundation – Work of Saint Pio of Pietrelcina) is a not-for-profit research hospital located in the city of San Giovanni Rotondo (FG), in the Puglia Region, Southern Italy.
As per Canon 1303 §1 of the Code of Canon Law, it has public, canonical and civil legal personality; it is therefore subject to the supervision of the Holy See and, on its behalf, of the pro-tempore Cardinal Secretary of State. 
Many of the stages that have thus far marked the history of the Work of San Pio of Pietrelcina have been achieved thanks to the loving generosity of many benefactors who, sharing the mission indicated by San Pio da Pietrelcina, the relief of suffering, wanted to donate to his work.

HISTORY
The hospital was founded and inaugurated by Saint Pio of Pietrelcina on May 5, 1956 with a capacity of 250 beds. It took on the status of Provincial Hospital on 4 August 1971 and then of Regional General Hospital on 2 June 1980, thus becoming part of the Italian National Healthcare System. Since 16 July 1991, with a Decree of the Minister of Health and the Minister of University and Scientific Research, it has been a Research Hospital. Originally, the object of its scientific activity was limited to genetic and hereditary-familial diseases; subsequently, the Minister of Health, by the 5 December 2012 Decree, extended the research areas of its competence to "Genetic diseases, innovative therapies and regenerative medicine". Recently, on the occasion of the presentation of the research lines for the three-year programme of the Italian Research Hospitals 2022-2024, Casa Sollievo identified “Diagnostic acitivity, Neurology and Oncology” as its main research thematic areas, thus becoming a polythematic Research Hospital.

MISSION
The Foundation's mission is to provide health care and carry out research activities. In addition, the Foundation offers training activities for its personnel.
Around 2,750 people work at the Foundation.
The Foundation (hereinafter “CSS”) consists of three structures based in San Giovanni Rotondo: the hospital Casa Sollievo, the polyclinic Giovanni Paolo II, where outpatient activities are carried out, and the ISBReMIT research center for regenerative medicine (Institute for Stem-cell Biology, Regenerative Medicine and Innovative Therapies); and the Mendel Institute in Rome, where research and diagnostic activities are carried out. In San Giovanni Rotondo, it also owns and runs a retirement home for the elderly.
In addition, CSS owns 3 hospitality facilities where affordable accommodation is offered to hospitalized patients’ relatives who have to assist them; and another facility (Casa Zeni) where accommodation is offered free of charge to the parents of the little patients hospitalized in the oncology-hematology unit.
Moreover, the Foundation includes the Padre Pio Prayer Groups Centre, which was also founded by San Pio and coordinates the Padre Pio prayers groups throughout the world, according to the Founder’s wish that Prayers Groups live and testify the importance of prayer and pray for CSS.
Lastly, CSS publishes a monthly periodical and posts on the Foundation’s official channels on the web updates on its research and clinical activity and its spiritual activity and the teachings of the Founder.
The hospital offers assistance also to people from underdeveloped countries. 
Moreover, a free-of-charge shuttle service has been provided for many years to radiotherapy patients coming from Bari and surrounding cities (Southern Puglia).

THE CLINICAL ACTIVITY
CSS has around 756 beds, 38 medical and surgical inpatient units, 26 operating rooms, in addition to services, diagnostic and multi-specialist outpatient units.
In 2022, the hospital recorded over 30,000 hospitalizations and 870,000 outpatient performances. 
Regarding the advanced technological equipment, CSS has 1 "Da Vinci" surgical robot, 1 PET/CT device, 3 linear accelerators, 4 CT devices, 1 CT simulator for radiotherapy, 4 NMR equipment, 3 digital angiographs, 2 gamma cameras and a RIS/PACS system for the filmless management of the radiology department.
Furthermore, CSS hosts an Umbilical Cord Bank and a Human Milk Bank.
Recent Achievements
In addition to the many important activities carried out in CSS, 3 new units have been opened: 1. a new Emergency Room hosting an Observation and Assessment Ward; 2. an Hematopoietic Stem Cell Transplant Center. 3. an Sub-Intensive Geriatric Unit. 
CSS has also established a Stroke Unit, a Lung Unit, a Breast Unit, a Head and Neck Unit, and a Molecular Tumor Board to guarantee appropriate, quality and homogeneous procedures.
Future goals
Important technological investments have been planned for the years 2023-2025 in the following areas: oncology/nuclear medicine, diagnostic imaging, ICU, and surgery. 

THE RESEARCH ACTIVITY
The research activity is conducted in the Polyclinic, the ISBReMIT research center and at the Mendel Institute, for a total of 17 research groups.
Recent achievements
The consolidated experience of the staff working in CSS in the study of genetic diseases since 1991 and the continuous updating of technologies, instrumentation and genomics and post-genomics skills have made it possible to direct the research and clinical-assistance activity towards two complementary research lines: "personalized medicine - system biomedicine" and "regenerative medicine" based on the study of tumor stem cells and the use of normal stem cells.
The scientific fields in which the Institute is mostly involved in "personalized medicine" concern the identification of the genetic causes of rare diseases and the identification of diagnostic, prognostic and predictive markers in complex pathologies, including tumor pathologies. Regarding the identification of the genetic causes of rare diseases, we use the new next generation sequencing (NGS) technologies and the skills acquired by the bioinformatics unit, one of the first established at national level. In parallel, the Institute boasts a large collection of induced pluripotent stem cells (iPSCs), produced from patient fibroblasts, in which pathogenetic variants have been identified, and use the skills acquired in differentiating them into mature cells, in particular astrocytes, neurons and oligodendrocytes.
Regarding regenerative medicine, two important studies were conducted and concluded: a phase I trial on anti-Multiple Sclerosis therapy based on the use of human neural stem cells, approved by the Ministry of Health and the Italian Medicines Authority AIFA (EudraCT code 2015-004855-37); and a phase I/II trial on anti-glioma therapy with biological drugs (EudraCT code: 2016-001761-92). The results of these studies will published in prestigious international journals.
In 2015, the new ISBReMIT Regenerative Medicine Research Center was started. It is a cutting-edge structure in terms of conception and equipment in the field of translational medicine for genetic, degenerative and oncological diseases. The structure hosts, together with the highly technologically equipped laboratories, a cell factory and a laboratory for the production of biopharmaceuticals under Good Manufacturing Practice, i.e. for clinical use, including somatic stem cells and iPS, vectors for gene therapy and biomaterials.
It should be noted that CSS has recently become part of three Networks of the Italian Research Centers: since 2016 it has been an Ordinary Associate of Alleanza Contro il Cancro; since December 2018, of the National Research Network on Aging; and, finally, since March 2020 of the Neuroscience Network. Starting from 2022, CSS has been part of the European reference networks for rare and uncommon diseases (European Reference Networks - ERN), in particular ERN-SKIN on diseases of dermatological interest, and ERN ReCONNET on musculoskeletal diseases and pathologies of the connective tissue.
Researchers publish about 200 scientific articles in the most renowned journals (Science, New England Journal of Medicine, Nature Genetics) every year. They are engaged both as Principal Investigators and as partners in research projects in the biomedical field and ICT, obtaining funds from the EU (H2020 and FP7) and national or regional calls.
CSS is also a partner in Research and Innovation projects funded by private and public bodies, e.g. from the EU both under Horizon 2020 and Horizon Europe, in the field of digital transformation of healthcare. The main areas of involvement concern Assistive Robotics, Artificial Intelligence, Big Data generated by consumer devices, eHealth, Digital Therapies, the Internet of Things and Cybersecurity.
Future goals
Starting from the identification of the genetic causes of diseases, the goal is to develop advanced therapies to bring to the patient's bedside and tailored to him/her.
Furthermore, at the end of 2023, the phase II study "Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis: A multicenter, randomized placebo controlled and biological endpoints clinical Trial" (EudraCt 2018-002373-22) will be launched. This involves the use of neural stem cells on patients suffering from Amyotrophic Lateral Sclerosis.

CONCLUSION
Casa Sollievo della Sofferenza was born of the visionary mind of a poor friar, one of the most important, recent and internationally recognized and prayed Saints, Saint Pio of Pietrelcina, right after the II World War, in a poor corner of the Southern Italy of those times. 
CSS, by its Statutes, is a not-for-profit organization. All the good work that has been done until now for the sick has been possible thanks to the generosity of donors and to the public and private funds that have been collected through the hard work of the Foundation’s researchers and clinicians, thus contributing importantly to the care of citizens from Southern Italy and underdeveloped countries and to the world research.

Fondazione di Religione e di Culto Casa Sollievo della Sofferenza - Opera di San Pio da Pietrelcina

We aim to mitigate catastrophic risks from transformative AI, which we believe could be developed in the next few decades.



The AI Risk Mitigation Fund (ARM Fund) is a non-profit fund making grants in technical research, policy, and training programs for new researchers to reduce catastrophic risks from advanced AI.

We are focussed on the following three areas.

Technical AI alignment research
Technical research can uncover dangerous capabilities before it’s too late, or enable designing future AI systems with enhanced interpretability, steerability, and possibility for human oversight.

Policy
Policy work aims to ensure that government regulation and corporate standards appropriately guard against catastrophic risks.

Training for new researchers
Investment has poured into AI capability development, yet strikingly few researchers are working on key problems in AI safety, particularly outside major industry labs. Grants in this area aim to bring new talent into the AI safety field.

Our mission is to mitigate catastrophic risks from transformative AI, which we believe could be developed in the next few decades.

Our team and history
Our team works hard to ensure you make the most effective donations possible. We have substantial experience managing large donations securely, professionally, and flexibly. We've collectively overseen tens of millions of dollars worth of donations to nonprofits based on careful analysis of their impactfulness and ability to use new funding.

What you can expect if you donate
When we receive a donation designated for the ARM Fund, we grant 100% of the value of the donation (minus any fees charged by payment processors) to organizations and individuals recommended by our team of expert grantmakers.

The ARM Fund does not take any fees from donations before the distribution (we fundraise separately for our overhead costs, which include wages for our grantmakers).

The ARM Fund will likely have a partially overlapping group of applicants as the Long-Term Future Fund. So while 100% of your donations will go directly to AI safety projects under the ARM Fund, your donations will likely have an indirect effect in freeing up some of LTFF’s other resources to be spent on other existential security interventions, including both in AI safety and in other LTFF focus areas like biosecurity.

Donors will have the option to join our quarterly mailing list tracking updates in AI safety, listing our grants, and more.

100% of your donation is tax-deductible to the extent allowed by US law. Your donation is made to Every.org, a tax-exempt US 501(c)(3) charity that grants unrestricted funds to Effective Ventures Foundation USA, Inc. on your behalf. As a legal matter, Every.org must provide any donations to Effective Ventures Foundation USA, Inc. on an unrestricted basis, regardless of any designations or restrictions made by you.

AI Risk Mitigation Fund

Support our mission to ensure trustworthy and safe AI at Apart Research.

We are active contributors and enablers of AI safety research. Our mission is to minimize the risks posed by large-scale AI applications to society. To this end, we conduct research to develop safer AI and nurture talent for AI safety research roles. We organize international research sprints focused on safety topics and support talented researchers in transforming their work into fully published articles.

Apart Research

Aquatic Life Institute is a 501(c)(3) non-profit focused on reducing the suffering of aquatic animals in the global food system.

Aquatic Life Institute (ALI) was founded in 2019 to address the critical and often overlooked issue of aquatic animal welfare. Recognizing that aquatic animals are the most exploited group of animals worldwide yet remain largely unprotected, ALI set out with a mission to drive systemic change and elevate aquatic animal welfare as a priority in global food systems.

Our theory of change is rooted in the belief that by influencing key stakeholders and decision makers, advancing policies, and fostering collaboration, we can drive systemic transformation for billions of aquatic animals. 

Building on this foundation, ALI has emerged as a thought leader, advocating for tangible improvements across the seafood supply chain. By engaging with key stakeholders, including corporations, certification schemes, and policymakers, we work to ensure that aquatic animals trapped in the food system receive the attention they deserve in decision-making processes relating to sustainability and food systems. 

ALI’s work is driven by evidence-based strategies and collaboration. This approach has earned ALI widespread recognition, including a 2024 Top Charity recommendation from Animal Charity Evaluators (ACE). This endorsement solidifies ALI’s position as one of the most effective organizations in the world advancing aquatic animal welfare. 

Aquatic Life Institute Inc

Phare Bio is using AI/deep learning to discover novel classes of antibiotics to address a looming crisis in antibiotic resistance.

Phare Bio is an ambitious social venture using novel AI and deep learning approaches to antimicrobial development in collaboration with Professor Jim Collins at MIT, a founder of the field of synthetic biology. Phare is a recipient of the Audacious Project, a collaborative funding initiative between TED and other non-profits to unlock social impact on a grand scale. 

The rapid evolution of antibiotic-resistant bacteria and a dwindling discovery pipeline have resulted in an antimicrobial resistance (AMR) crisis. Today, according to the Centers for Disease Control and Prevention, someone in the U.S. acquires a resistant infection every 11 seconds; every 15 minutes someone dies as a result of one. Covid-19 has only highlighted the urgency with approximately 15% of hospitalized patients suffering from bacterial co-infections. There is a critical need for new antibiotics, and yet, pharmaceutical and biotechnology companies have largely abandoned the space in favor of more lucrative markets. 

Phare Bio launched in 2020 to tackle this critical unmet need with the latest advances in machine learning to develop entirely novel antibiotics. Integrating world-class expertise and decades of experience in artificial intelligence (AI), bioengineering, and life sciences, Phare is targeting the world's most deadly pathogens, such as Acinetobacter and Pseudomonas, with the goal of developing seven novel classes of antibiotics in seven years. 

Phare Bio

Communicating the best research and data to understand big global problems and make progress against them

Poverty, disease, hunger, climate change, war, existential risks, and inequality: The world faces many great and terrifying problems. Our World in Data focuses on communicating the best research and data that helps us understand and find solutions to the world’s largest problems.


Our World in Data publishes an open-access publication where users can understand the state of the world today, where we are making progress and where we are falling behind. Through interactive data visualizations we can see how the world has changed; by summarizing the scientific literature we can understand why. We cover everything from global poverty to natural disasters, education and health, democracy; we have over 13,000 charts across hundreds of topics.


Our World in Data is free, open-source and provided as a public good. It has millions of users every month, and is cited in research and media across the world every day. This allows millions of people to understand the large problems the world is facing, and how we can solve them.

Our World in Data

Terra Praxis designs and implements strategies that leverage science, technology and energy innovation for a prosperous planet

We co-founded TerraPraxis to design and implement strategies that leverage science, technology and energy innovation for a prosperous planet. Our mission is to innovate and accelerate scalable, equitable solutions for unsolved areas of the climate challenge. 

Our special focus is on enabling high-impact rapid transitions for neglected parts of the decarbonization challenge. 

We work with an extensive global network to define, incubate and initiate scalable strategies that fulfil the twin missions of prosperity and decarbonization. 

Terra Praxis

The Top Charities Fund supports the highest-priority funding needs among our top charities.

We find and recommend outstanding giving opportunities and publish our research to help donors give more effectively and with greater confidence.

All donations here support our Top Charities Fund. Donations to the Top Charities Fund are granted on a rolling basis to support cost-effective funding opportunities at our top charities. We use our latest research to grant the funds to the top charity (or charities) where we believe they’ll do the most good.

Learn more and view past grants at https://www.givewell.org/top-charities-fund


Photo caption: At health centers in Sierra Leone supported by Helen Keller Intl, mothers who bring their children in for twice-yearly vitamin A supplemention can also receive comprehensive counseling about birth control options that are available to them free of charge. Combining family planning and children's healthcare services benefits both mother and child. 2019.

Top Charities Fund

innovative award-winning non-profit journalism organization dedicated to raising awareness of underreported global issues through direct support for quality journalism across all media platforms and a unique program of outreach and education to schools and universities. 

We award more than $2 million a year in direct support to journalism at a time of financial stress in the news industry, making possible more than 600 stories annually in print, broadcast, and digital news outlets, as well as documentaries, books, and exhibitions. Our projects run in a wide variety of respected national, local, and international news outlets. Since our founding in 2006, Pulitzer Center reporting projects have won Emmys, George Polk Awards, National Magazine Awards, Overseas Press Club Awards, Peabody Awards, and Pulitzer Prizes.

We educate students and the public in more than 500 events a year featuring our journalist-grantees in conversations, exhibitions, and interactive events in public venues, schools, and colleges. Our in-person audience engagement builds trust in news by giving audiences fact-based reporting on global issues that affect them at home.

We support journalists, stories, and workplaces that represent and illuminate diversity and inclusion in all forms. Funded by foundations and donors like you, we are a tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code. You can support our mission here.

The Pulitzer Center is not affiliated with Columbia University's Pulitzer Prizes. 

Pulitzer Center on Crisis Reporting

Prevention, control and treatment of malaria and other communicable diseases among vulnerable populations.

Malaria Consortium US, Inc. (MC-US) is a registered 501(c)(3) public charity and shares the mission of Malaria Consortium, a globally recognized organization committed to reducing deaths and illnesses caused by malaria and other preventable and treatable diseases across Africa and Asia.

Our mission is to save lives and improve health in Africa and Asia through evidence-based programs that tackle malaria and other priority diseases while advancing universal health coverage (UHC). In the US, we build partnerships with foundations, donors, and philanthropic organizations to ensure that every contribution makes a lasting impact for those most in need.

As a leader in malaria control and elimination, our work focuses on interventions such as seasonal malaria chemoprevention (SMC), malaria vaccines, disease surveillance, and integrated child health services. We work in collaboration with governments, communities, and health systems to improve access to essential healthcare and strengthen delivery of services in underserved and hard-to-reach areas.

As a leader in interventions such as chemoprevention and vector control, we rely on evidence and our expertise to deliver established interventions, influence other effective interventions and guide new strategies to reduce the burden of malaria, pneumonia, dengue, malnutrition and diarrhea. We work with communities and all levels of the health system to improve access to and demand for primary healthcare services and overall quality of care.

Our tailored interventions seek to improve equity by providing quality, affordable health services to marginalized populations (particularly women and girls and those living in hard-to-reach areas). To ensure barriers to achieving UHC are addressed and to encourage sustainability, we work closely with governments to integrate our programs within existing health systems and structures in the countries in which we work.

We promote disease surveillance as a core intervention to engage communities to improve the quality and accessibility of routine health information by using digital tools and approaches that strengthen the linkages between case-level data and national health information systems. We combine capacity development at community level with the use of innovative tools and platforms to enhance local capabilities to interpret and use these data most effectively.

All of our work is informed by our core values: accountability, integrity, dignity and equity.

Malaria Consortium

Protecting free expression and enabling secure global communication through open source privacy technology.

Long before we knew that it would be called Signal, we knew what we wanted it to be. Instead of teaching the rest of the world cryptography, we wanted to see if we could develop cryptography that worked for the rest of the world. At the time, the industry consensus was largely that encryption and cryptography would remain unusable, but we started Signal with the idea that private communication could be simple.

Since then, we’ve made some progress. We’ve built a service used by millions, and software used by billions. The stories that make it back to us and keep us going are the stories of people discovering each other in moments where they found they could speak freely over Signal, of people falling in love over Signal, of people organizing ambitious plans over Signal. When we ask friends who at their workplace is on Signal and they respond “every C-level executive, and the kitchen staff.” When we receive a subpoena for user data and have nothing to send back but a blank sheet of paper. When we catch that glimpse of “Signal blue” on a metro commuter’s phone and smile.

However, we’ve always wanted to do much more, and our limitations have often been challenging. Over the lifetime of the project, there have only been an average of 2.3 full-time software developers, and the entire Signal team has never been more than 7 people. With three client platforms to develop, a service to build and run, a growing list of integrations to assist with, and millions of users to support, that has often left us wanting.

Even so, Signal has never taken VC funding or sought investment, because we felt that putting profit first would be incompatible with building a sustainable project that put users first. As a consequence, Signal has sometimes suffered from our lack of resources or capacity in the short term, but we’ve always felt those values would lead to the best possible experience in the long term. The Signal Foundation completes our vision of Signal operating as part of a full 501(c)(3).

Signal Technology Foundation

We search for the charities that save or improve lives the most per dollar.

Our goal is to produce the world's top research on where to give. Free, for everyone.

We recommend a small number of charities that do an incredible amount of good. 

If you would like to donate to our giving funds or individual top charities, please see our projects below. You can donate here or on the Unrestricted Fund page below to make an unrestricted gift to GiveWell to support the full spectrum of our grantmaking and underwrite our ability to continue doing what we do.

GiveWell

148788709

1578280819

1873740264

2052641908

2088874155

We are a nonprofit, so we rely on the generosity of donors like you.

Choose a donation for Every.org

2109878826

2310049938

2551237796

2576076625

2594001433

283252266

2883383521

3026174861

316638097

3170054231

338811242

3705164611

3842241318

3934974605

4167807122

4287068530

440668958

1287028958

2729980760

2939442496

3440869557

671754822

87081813

1014384873

1112422858

153399038

2028390811

220342792

2266630408

2519810400

2539558839

2826465835

2843798242

2898624300

3259439560

339774024

3642494300

3902459442

4250940449

472232120

585491400

641510716

91682487

Artist, Herbalist, Breathwork Facilitator and Student of Life. www.daniellecaners.com 

I donate to wildlife conservation to allow those heroes who dedicate their lives to protecting wildlife can continue their amazing work.

founder @ camp.org, expa.com, uber.com & mix.com

.css-1wjgqn{display:inline-block;--textSize:1.5rem;--lineHeight:1.7999999999999998rem;line-height:var(--lineHeight);font-size:var(--textSize);width:100%;}Research

Mersal Foundation for Charity and Development

The Sweat For Breath Foundation

Fungi Foundation

Fungi Foundation

Cuddles Foundation

Zig Software Foundation Inc

Research